​

Replimune Group (REPL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

REPL Stock Forecast

Replimune Group (REPL) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $25.50, with a high of $43.00 and a low of $13.00. This represents a 704.42% increase from the last price of $3.17.

- $9 $18 $27 $36 $45 High: $43 Avg: $25.5 Low: $13 Last Closed Price: $3.17

REPL Stock Rating

Replimune Group stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (57.14%), 5 Hold (35.71%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 5 8 Strong Sell Sell Hold Buy Strong Buy

REPL Price Target Upside V Benchmarks

TypeNameUpside
StockReplimune Group704.42%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$23.00
Last Closing Price$3.17$3.17$3.17
Upside/Downside--625.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2545---9
Jun, 2553---8
May, 2553---8
Apr, 2553---8
Mar, 2553---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 22, 2025Evan SeigermanBMO Capital$27.00$13.09106.26%751.74%
Dec 03, 2024Roger SongJefferies$19.00$14.4831.22%499.37%
Jun 07, 2024Robert BurnsH.C. Wainwright$17.00$7.11139.10%436.28%
Jun 04, 2024Peter LawsonBarclays$13.00$5.37142.09%310.09%
May 17, 2024Evan SeigermanBMO Capital$14.00$6.85104.38%341.64%
Dec 12, 2022BMO Capital$70.00$25.00180.00%2108.20%
Dec 07, 2022Leerink Partners$34.00$23.0947.25%972.56%
Oct 03, 2022Leerink Partners$30.00$17.2773.71%846.37%
Aug 17, 2022Piper Sandler$43.00$20.62108.54%1256.47%
Aug 05, 2022Leerink Partners$37.00$20.3781.64%1067.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 22, 2025BMO CapitalOutperformOutperformhold
Dec 03, 2024JefferiesBuyBuyhold
Nov 22, 2024BMO CapitalOutperformOutperformhold
Sep 10, 2024BMO CapitalOutperformOutperformhold
Sep 10, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Rodman & RenshawBuyinitialise
Jun 07, 2024BMO CapitalOutperformOutperformhold
Jun 07, 2024H.C. WainwrightBuyBuyhold
Jun 04, 2024BarclaysOverweightOverweighthold
May 17, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-3.24-----
Avg Forecast$-3.05$-2.74$-2.40$-2.10$-1.19$0.29
High Forecast$-2.93$-2.68$-2.30$-1.77$0.26$0.98
Low Forecast$-3.25$-2.79$-2.53$-2.75$-4.08$-0.06
Surprise %6.23%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported------
Avg Forecast-$8.75M$53.56M$135.57M$333.85M$606.00M
High Forecast-$25.12M$160.55M$389.25M$958.60M$1.74B
Low Forecast-$527.05K$3.98M$8.17M$20.11M$36.51M
Surprise %------

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-215.79M-----
Avg Forecast$-209.96M$-181.99M$-161.00M$-150.38M$-79.22M$18.97M
High Forecast$-195.05M$-178.51M$-153.27M$-117.88M$17.56M$65.13M
Low Forecast$-216.10M$-185.47M$-168.73M$-182.87M$-271.93M$-4.21M
Surprise %2.78%-----

REPL Forecast FAQ

Is Replimune Group stock a buy?

Replimune Group stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Replimune Group is a favorable investment for most analysts.

What is Replimune Group's price target?

Replimune Group's price target, set by 14 Wall Street analysts, averages $25.5 over the next 12 months. The price target range spans from $13 at the low end to $43 at the high end, suggesting a potential 704.42% change from the previous closing price of $3.17.

How does Replimune Group stock forecast compare to its benchmarks?

Replimune Group's stock forecast shows a 704.42% upside, outperforming the average forecast for the healthcare stocks sector (18.80%) and outperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Replimune Group over the past three months?

  • July 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 62.50% Strong Buy, 37.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 62.50% Strong Buy, 37.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Replimune Group’s EPS forecast?

Replimune Group's average annual EPS forecast for its fiscal year ending in March 2025 is $-2.74, marking a -15.43% decrease from the reported $-3.24 in 2024. Estimates for the following years are $-2.4 in 2026, $-2.1 in 2027, $-1.19 in 2028, and $0.29 in 2029.

What is Replimune Group’s revenue forecast?

Replimune Group's average annual revenue forecast for its fiscal year ending in March 2025 is $8.75M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $53.56M, followed by $135.57M for 2027, $333.85M for 2028, and $606M for 2029.

What is Replimune Group’s net income forecast?

Replimune Group's net income forecast for the fiscal year ending in March 2025 stands at $-182M, representing a -15.66% decrease from the reported $-216M in 2024. Projections indicate $-161M in 2026, $-150M in 2027, $-79.218M in 2028, and $18.97M in 2029.